Incannex Healthcare's mission is to create premier, ethical pharmaceutical drugs and therapies for patients with unmet medical needs, in all instances fulfilling regulatory requirements of the Food and Drug Administration and other relevant regulatory agencies.
Advanced clinical trials with both psychedelic- and cannabinoid-based compounds.
Six lead initiatives in the Company's pipeline with 5 either in human clinical trials or preparing to commence a clinical trial.
Cash and cash equivalents of AU$19,770,505 as of December 31, 2021.
Recently uplisted to the NASDAG (March 1, 2022), under the symbol "IXHL".